


IN THE CLAIMS:**Claim 1 (cancelled).****Claim 2 (currently amended):** A compound according to claim ~~1~~ 27 of the formula

Ia:



(Ia)

wherein:

ring C^a is indolyl, indazolyl or azaindolyl; R^{1a} is selected from oxo, hydroxy, C_{1-2} alkoxymethyl, amino, halogeno, C_{1-3} alkyl, C_{1-3} alkoxy, trifluoromethyl, cyano, nitro, C_{1-3} alkanoyl,(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27,(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27,(iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim ~~1~~ 27; R^2 is as defined in claim ~~1~~ 27; m_a is 0, 1, 2 or 3; Z^a is -O- or -S-; and n_a is 0, 1 or 2;with the proviso that at least one R^2 is selected from (i), (ii), (iii), (iv) or (v) as defined inclaim ~~1~~ 27 in the definitions of R^2 , and/or R^{1a} is selected from (i), (ii) and (iii) as defined herein,or R^2 is 6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.


Claim 3 (original): A compound according to claim 2 wherein m is 2.

Claim 4 (currently amended): A compound according to claim ~~+27~~ or claim 2 wherein R^2 is selected from one of the five groups:

- (i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~+27~~;
- (ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~+27~~;
- (iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim ~~+27~~;
- (iv) $Q^{28}C_{1-5}alkylX^1$ -, $Q^{28}C_{2-5}alkenylX^1$ - or $Q^{28}C_{2-5}alkynylX^1$ - wherein Q^{28} and X^1 are as defined in claim ~~+27~~; and
- (v) $Q^{29}C_{1-5}alkylX^1$ -, $Q^{29}C_{2-5}alkenylX^1$ - or $Q^{29}C_{2-5}alkynylX^1$ - wherein Q^{29} and X^1 are as defined in claim ~~+27~~;

and/or R^2 represents methoxy, or R^2 represents 6,7-methylenedioxy or 6,7-ethylenedioxy.

Claim 5 (currently amended): A compound according to claim ~~+27~~ of the formula II:



(II)

wherein:

ring C^a is indolyl, indazolyl or azaindolyl;

R^{1a} is selected from oxo, hydroxy, C_{1-2} alkoxymethyl, amino, halogeno, C_{1-3} alkyl, C_{1-3} alkoxy, trifluoromethyl, cyano, nitro, C_{1-3} alkanoyl,

- (i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~+27~~;

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~4~~ 27; and

(iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim ~~4~~ 27;

R^{2a} and R^{2b} , are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, $C_{1-3}alkyl$, $C_{1-3}alkoxy$, $C_{1-3}alkylsulphanyl$, $-NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a} , which may be the same or different, each represents hydrogen or $C_{1-3}alkyl$),

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~4~~ 27,

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~4~~ 27,

(iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim ~~4~~ 27,

(iv) $Q^{28}C_{1-5}alkylX^1$ -, $Q^{28}C_{2-5}alkenylX^1$ - or $Q^{28}C_{2-5}alkynylX^1$ - wherein Q^{28} and X^1 are as defined in claim ~~4~~ 27 or

(v) $Q^{29}C_{1-5}alkylX^1$ -, $Q^{29}C_{2-5}alkenylX^1$ - or $Q^{29}C_{2-5}alkynylX^1$ - wherein Q^{29} and X^1 are as defined in claim ~~4~~ 27,

or R^{2a} and R^{2b} together form 6,7-methylenedioxy or 6,7-ethylenedioxy;

Z^a is -O- or -S-;

and n_a is 0, 1 or 2;

with the proviso that at least one of R^{2a} and R^{2b} is selected from (i), (ii), (iii), (iv) or (v) as defined herein and/or R^{1a} is selected from (i), (ii) and (iii) as defined herein, or R^{2a} and

R^{2b} together form 6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.

Claim 6 (original): A compound according to claim 5 wherein R^{1a} is fluoro or methyl.

Claim 7 (currently amended): A compound according to claim 5 ~~or claim 6~~ wherein Z^a is -O-.

Claim 8 (currently amended): A compound according to ~~claim 5~~ any one of claims 5, 6 and 7 wherein R^{2a} is methoxy and R^{2b} is selected from one of the five following groups:

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~4~~ 27;


- (ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim+27;
- (iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim+27;
- (iv) $Q^{28}C_{1-5}alkylX^1$ -, $Q^{28}C_{2-5}alkenylX^1$ - or $Q^{28}C_{2-5}alkynylX^1$ - wherein Q^{28} and X^1 are as defined in claim+27; and
- (v) $Q^{29}C_{1-5}alkylX^1$ -, $Q^{29}C_{2-5}alkenylX^1$ - or $Q^{29}C_{2-5}alkynylX^1$ - wherein Q^{29} and X^1 are as defined in claim+27.

Claim 9 (currently amended): A compound according to claim 5 ~~any one of claims 5, 6 and 7~~ wherein R^{2b} is methoxy and R^{2a} is selected from one of the five following groups:

- (i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim+27;
- (ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim+27;
- (iii) $Q^{21}W^4C_{1-5}alkylX^1$ - wherein Q^{21} , W^4 and X^1 are as defined in claim+27;
- (iv) $Q^{28}C_{1-5}alkylX^1$ -, $Q^{28}C_{2-5}alkenylX^1$ - or $Q^{28}C_{2-5}alkynylX^1$ - wherein Q^{28} and X^1 are as defined in claim+27; and
- (v) $Q^{29}C_{1-5}alkylX^1$ -, $Q^{29}C_{2-5}alkenylX^1$ - or $Q^{29}C_{2-5}alkynylX^1$ - wherein Q^{29} and X^1 are as defined in claim+27.

Claim 10 (original): A compound according to any one of claims 2 to 8 wherein the ring C^a is indol-5-yl, indol-6-yl, 7-azaindol-5-yl, indazol-5-yl or indazol-6-yl.

Claim 11 (currently amended): A compound according to claim 5 of the formula IId:



(IId)

wherein:


M is -CH- or -N-;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;


R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

one of R^{2a} and R^{2b} is methoxy and the other is Q¹X¹ wherein X¹ is as defined in claim 27 and Q¹ is selected from one of the following ten groups:

- 1) Q², wherein Q² is a heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



which heterocyclic group bears at least one substituent selected from C₂₋₅alkenyl,

C₂₋₅alkynyl, C₁₋₄fluoroalkyl, C₁₋₄alkanoyl, aminoC₁₋₆alkanoyl,

C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₄fluoroalkanoyl,

carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl,

C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₄alkylsulphonyl

and C₁₋₄fluoroalkylsulphonyl and which heterocyclic group may optionally bear a

further 1 or 2 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₄fluoroalkyl,

C₁₋₄alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl,

di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₄fluoroalkanoyl, carbamoyl,

C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl,

C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₄alkylsulphonyl,


C₁₋₄fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl,

C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl,

C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino,


di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl,

C_{1-4} alkylamino C_{1-4} alkoxy, di(C_{1-4} alkyl)amino C_{1-4} alkoxy and a group
 $-(O)_f(C_{1-4}alkyl)_g ring D_n$ (wherein f is 0 or 1, g is 0 or 1 and ring D is selected
 from pyrrolidinyl, piperidinyl, piperazinyl,




which heterocyclic group may bear one or more substituents selected from
 C_{1-4} alkyl);

- 2) $C_{1-5}alkylW^1Q^2_n$ (wherein W^1 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-OC(O)-$,
 $-NQ^3C(O)-$, $-C(O)NQ^4-$, $-SO_2NQ^5-$, $-NQ^6SO_2-$ or $-NQ^7-$ (wherein Q^3 , Q^4 , Q^5 , Q^6
 and Q^7 each independently represents hydrogen, $C_{1-2}alkyl$, $C_{1-2}alkoxyC_{2-3}alkyl$,
 $C_{2-5}alkenyl$, $C_{2-5}alkynyl$ or $C_{1-4}haloalkyl$) and Q^2 is as defined herein;
- 3) $C_{1-5}alkylQ^2_n$ (wherein Q^2 is as defined herein);
- 4) $C_{2-5}alkenylQ^2_n$ (wherein Q^2 is as defined herein);
- 5) $C_{2-5}alkynylQ^2_n$ (wherein Q^2 is as defined herein);
- 6) $C_{1-4}alkylW^2C_{1-4}alkylQ^2_n$ (wherein W^2 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$,
 $-NQ^8C(O)-$, $-C(O)NQ^9-$, $-SO_2NQ^{10}-$, $-NQ^{11}SO_2-$ or $-NQ^{12}-$ (wherein Q^8 , Q^9 , Q^{10} ,
 Q^{11} and Q^{12} each independently represents hydrogen, $C_{1-3}alkyl$,
 $C_{1-3}alkoxyC_{2-3}alkyl$, $C_{2-5}alkenyl$, $C_{2-5}alkynyl$ or $C_{1-4}haloalkyl$) and Q^2 is as
 defined herein);
- 7) $C_{2-5}alkenylW^2C_{1-4}alkylQ^2_n$ (wherein W^2 and Q^2 are as defined herein);
- 8) $C_{2-5}alkynylW^2C_{1-4}alkylQ^2_n$ (wherein W^2 and Q^2 are as defined herein);
- 9) $C_{1-4}alkylQ^{13}(C_{1-4}alkyl)_j(W^2)_kQ^{14}_n$ (wherein W^2 is as defined herein, j is 0 or 1, k is
 0 or 1, and Q^{13} and Q^{14} are each independently selected from pyrrolidinyl,
 piperidinyl, piperazinyl,




which heterocyclic group may bear 1, 2 or 3 substituents selected from
 $C_{2-5}alkenyl$, $C_{2-5}alkynyl$, $C_{1-4}fluoroalkyl$, $C_{1-4}alkanoyl$, amino $C_{1-6}alkanoyl$,

C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₄fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₄alkylsulphonyl, C₁₋₄fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_gringD-$ (wherein f is 0 or 1, g is 0 or 1 and ring D is selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



which heterocyclic group may bear one or more substituents selected from

C₁₋₄alkyl}, with the proviso that at least one of Q¹³ and Q¹⁴ bears at least one

substituent selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₄fluoroalkyl, C₁₋₄alkanoyl,


aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl,

C₁₋₄fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl,


carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl,

C₁₋₄alkylsulphonyl and C₁₋₄fluoroalkylsulphonyl}; and

10) C₁₋₄alkylQ¹³C₁₋₄alkanoylQ¹⁴ⁿ wherein Q¹³ is as defined herein and Q¹⁴ⁿ is selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



wherein Q¹⁴ⁿ is linked to C₁₋₆alkanoyl through a nitrogen atom;

and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in Q¹X¹-


which is linked to X¹ may bear one or more substituents selected from hydroxy,

halogeno and amino;


or a salt thereof.

Claim 12 (currently amended): A compound according to claim 11 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is selected from one of the following four groups:

- 1) Q^2 -(wherein Q^2 is a heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,




and




,

which heterocyclic group bears one substituent selected from C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-4} alkanoyl, amino C_{1-6} alkanoyl, C_{1-4} alkylamino C_{1-6} alkanoyl, di(C_{1-4} alkyl)amino C_{1-6} alkanoyl, C_{1-6} fluoroalkanoyl, carbamoyl, C_{1-4} alkylcarbamoyl, di(C_{1-4} alkyl)carbamoyl, carbamoyl C_{1-6} alkyl, C_{1-4} alkylcarbamoyl C_{1-6} alkyl, di(C_{1-4} alkyl)carbamoyl C_{1-6} alkyl, C_{1-4} alkylsulphonyl and C_{1-4} fluoroalkylsulphonyl;

- 2) C_{1-5} alkyl Q^2 -(wherein Q^2 is as defined herein);
 3) C_{1-4} alkyl W^2C_{1-4} alkyl Q^2 -(wherein W^2 is as defined in claim 11 and Q^2 is as defined herein);
 4) C_{1-4} alkyl $Q^{13}(C_{1-4}$ alkyl) $_j(W^2)_kQ^{14}$ -(wherein W^2 is as defined in claim 11, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



,


which heterocyclic group may bear 1, 2 or 3 substituents selected from C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-4} alkanoyl, amino C_{1-6} alkanoyl, C_{1-4} alkylamino C_{1-6} alkanoyl, di(C_{1-4} alkyl)amino C_{1-6} alkanoyl, C_{1-6} fluoroalkanoyl, carbamoyl, C_{1-4} alkylcarbamoyl, di(C_{1-4} alkyl)carbamoyl, carbamoyl C_{1-6} alkyl, C_{1-4} alkylcarbamoyl C_{1-6} alkyl, di(C_{1-4} alkyl)carbamoyl C_{1-6} alkyl, C_{1-4} alkylsulphonyl,

C₁₋₄fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl; with the proviso that at least one of Q¹³ and Q¹⁴ bears at least one substituent selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₄alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₄alkylsulphonyl and C₁₋₄fluoroalkylsulphonyl);

and additionally wherein any C₁₋₅alkyl group in Q¹X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 13 (currently amended): A compound according to claim 5 of the formula

IIh:



(IIh)

wherein:

M and T each independently represents a carbon atom or a nitrogen atom with the proviso that M and T cannot both be nitrogen atoms;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

either R^{2a} and R^{2b} form 6,7-methylenedioxy or one of R^{2a} and R^{2b} is methoxy and the other is selected from one of the following four groups:

(a) Q¹X¹- wherein X¹ is -O- and Q¹ is selected from one of the following three groups:

1) Q²- (wherein Q² is a heterocyclic group selected from pyrrolidinyl, piperidinyl and piperazinyl, which heterocyclic group bears one substituent selected from C₂₋₅alkenyl, C₂₋₅alkynyl, ~~C₁₋₆fluoroalkyl~~, C₁₋₆alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl and C₁₋₆alkylsulphonyl;

2) C₁₋₅alkylQ²- (wherein Q² is as defined herein); and

3) C₁₋₄alkylW²C₁₋₄alkylQ²- (wherein W² represents -O- and Q² is as defined herein);

and additionally wherein any C₁₋₅alkyl group in Q¹X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy);

(b) Q²¹W⁴C₁₋₅alkylX¹- (wherein X¹ is -O-, W⁴ is NQ²⁶- (wherein Q²⁶ is hydrogen or C₁₋₃alkyl) and Q²¹ is C₂₋₅alkynyl);

(c) Q²⁸C₁₋₅alkylX¹- wherein X¹ is -O- and Q²⁸ is an imidazolidinyl group which bears two oxo substituents and one C₁₋₆alkyl group which C₁₋₆alkyl group bears a hydroxy substituent on the carbon atom which is linked to the imidazolidinyl group; and

(d) Q²⁹C₁₋₅alkylX¹- wherein X¹ is -O- and Q²⁹ is a group 1,4-dioxa-8-azaspiro[4.5]dec-8-yl;

or a salt thereof.

Claim 14 (currently amended): A compound according to claim ~~1~~ 27 selected from:

4-(7-azaindol-5-yloxy)-7-methoxy-6-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)-quinazoline,

6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(7-azaindol-5-yloxy)-7-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[[[(2S)-1-isobutyrylpyrrolidin-2-yl]methoxy]-6-methoxyquinazoline,

4-(7-azaindol-5-yloxy)-6-methoxy-7-[3-(4-carbamoylpiperazin-1-yl)propoxy]quinazoline,
 6-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,
 6-[(1-acetylpiperidin-4-yl)methoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,
 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,
 4-(7-azaindol-5-yloxy)-7-[3-(4-carbamoylmethyl)piperazin-1-yl]propoxy]-6-methoxyquinazoline,
~~4-(7-azaindol-5-yloxy)-7-[2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy]-6-methoxyquinazoline,~~
 4-(7-azaindol-5-yloxy)-6-methoxy-7-[3-(4-prop-2-yn-1-yl)piperazin-1-yl]propoxy]-quinazoline,
 7-[1-(*N,N*-dimethylaminoacetyl)piperidin-4-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol)-5-yloxy]-6-methoxyquinazoline,
 and salts thereof.

Claim 15 (currently amended): A compound according to claim ~~1~~ 27 selected from:

6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxyquinazoline,
 7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,
 4-(7-azaindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)-quinazoline,
 4-(7-azaindol-5-yloxy)-6-methoxy-7-[2-(*N*-methyl-*N*-prop-2-yn-1-ylamino)ethoxy]-quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxy-6-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)quinazoline,
 6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoroindol-5-yloxy)-7-methoxyquinazoline,
 7-[(1-acetylpiperidin-4-yl)methoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
 7-[(2*S*)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-[(2*R*)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-
6-methoxyquinazoline,

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)-
piperidin-4-ylmethoxy]quinazoline,~~

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)-
piperazin-1-yl]propoxy}quinazoline,~~

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)-
piperazin-1-yl]ethoxy}quinazoline,~~

~~7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-
methoxyquinazoline,~~

7-{2-[2-(4-acetylpiperazin-1-yl)ethoxy]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)-
oxy]-6-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-[(1-isobutyrylpiperidin-4-yl)methoxy]-6-
methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-[(2*R*)-1-isobutyrylpyrrolidin-2-yl]-
methoxy}-6-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[[1-(methylsulfonyl)piperidin-4-yl]
methoxy]quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[(2*S*)-1-(methylsulfonyl)-
pyrrolidin-2-yl]methoxy}quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[(2*R*)-1-(methylsulfonyl)-
pyrrolidin-2-yl]methoxy}quinazoline,

7-[3-(4-allylpiperazin-1-yl)propoxy]-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,

4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]-
propoxy}quinazoline,

~~7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)-
oxy]-6-methoxyquinazoline,~~

7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-(1*H*-indol-5-yloxy)-6-methoxyquinazoline,

7-[(2*S*)-1-carbamoylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-
methoxyquinazoline,

7-{3-[4-carbamoylpiperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
7-{3-[2,5-dioxo-4-(1-hydroxy-1-methylethyl)imidazolidin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
6-[(1-acetylpiperidin-4-yl)oxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,
4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxy-6-{[1-(methylsulphonyl)piperidin-4-yl]oxy}-quinazoline,
4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{2-[*N*-methyl-*N*-(2-propynyl)-amino]ethoxy}quinazoline,
7-[3-(4-acetylpiperazin-1-yl)propoxy]-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-quinazoline,
7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
7-[3-(4-carbamoylmethylpiperazin-1-yl)propoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
~~7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,~~
4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{(2*R*)-2-hydroxy-3-[4-prop-2-yn-1-yl-piperazin-1-yl]propoxy}-6-methoxyquinazoline,
7-{(2*R*)-3-[(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
7-{(2*R*)-3-[4-acetylpiperazin-1-yl]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,
and salts thereof.


Claim 16 (currently amended): A compound according to claim ~~4~~ 27 which is 7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yl)oxy)-6-methoxyquinazoline and salts thereof.

Claim 17 (currently amended): A compound according to claim ~~1~~ 27 which is 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline and salts thereof.

Claim 18 (currently amended): A compound according to claim ~~1~~ 27, claim 2 or claim 5 in the form of a pharmaceutically acceptable salt.


Claim 19 (currently amended): A process for the preparation of a compound according to claim ~~1~~ 27 of the formula I or salt thereof which comprises:

(a) the reaction of a compound of the formula III:



(III)

(wherein R^2 and m are as defined in claim ~~1~~ 27 and L^1 is a displaceable moiety), with a compound of the formula IV:




(IV)

(wherein ring C, R^1 , Z and n are as defined in claim ~~1~~ 27);

(b) a compound of formula I and salts thereof wherein at least one R^2 is R^5X^1 , Q^1X^1 , $Q^{15}W^3$ or $Q^{21}W^4C_{1-5}alkylX^1$, wherein R^5 , Q^1 , Q^{15} , W^3 , Q^{21} and W^4 are as defined in claim ~~1~~ 27, and X^1 is -O-, -S-, -OC(O)- or -NR¹⁰- (wherein R^{10} independently represents hydrogen,

C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) may be prepared by the reaction of a compound of the formula V:




(V)

(wherein ring C, Z, W^3 , R^1 , R^2 and n are as defined in claim 1 and X^1 is as defined in this section and s is an integer from 0 to 2) with one of the compounds of the formulae VIa-d:





(wherein R^5 , Q^1 , Q^{15} , Q^{21} and W^4 are as defined in claim 1 and L^1 is as defined herein);

- (c) a compound of the formula I and salts thereof wherein at least one R^2 is R^5X^1 , Q^1X^1 , $Q^{15}W^3$ or $Q^{21}W^4C_{1-5}alkylX^1$, wherein R^5 , Q^1 , Q^{15} , W^3 , Q^{21} and W^4 are as defined in claim 1, and X^1 is -O-, -S-, -OC(O)- or -NR¹⁰- (wherein R^{10} represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) may be prepared by the reaction of a compound of the formula VII:



(VII)


with one of the compounds of the formulae VIIIa-d:



(wherein s and L¹ are as defined herein, R¹, R², R⁵, Q¹, Q¹⁵, W³, Q²¹, W⁴, ring C, Z and n are all as defined in claim + 27 and X¹ is as defined in this section);

- (d) a compound of the formula I and salts thereof wherein at least one R² is R⁵X¹, Q¹X¹, Q²¹W⁴C₁₋₅alkylX¹, Q²⁸C₁₋₅alkylX¹ or Q²⁹C₁₋₅alkylX¹ wherein X¹ is as defined in claim + 27, R⁵ is C₁₋₅alkylR¹¹³, wherein R¹¹³ is selected from one of the following nine groups:
- 1) X¹⁹C₁₋₃alkyl- (wherein X¹⁹ represents -O-, -S-, -SO₂-, -NR¹¹⁴C(O)- or -NR¹¹⁵SO₂- (wherein R¹¹⁴ and R¹¹⁵ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
 - 2) NR¹¹⁶R¹¹⁷- (wherein R¹¹⁶ and R¹¹⁷ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
 - 3) X²⁰C₁₋₅alkylX⁵R²²- (wherein X²⁰ represents -O-, -S-, -SO₂-, -NR¹¹⁸C(O)-, -NR¹¹⁹SO₂- or -NR¹²⁰- (wherein R¹¹⁸, R¹¹⁹, and R¹²⁰ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and X⁵ and R²² are as defined in claim + 27);
 - 4) R²⁸- (wherein R²⁸ is as defined in claim + 27);

- 5) $X^{21}R^{29}$ (wherein X^{21} represents -O-, -S-, -SO₂-, -NR¹²¹C(O)-, -NR¹²²SO₂-, or -NR¹²³- (wherein R¹²¹, R¹²², and R¹²³ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim+27); and
- 6) $X^{22}C_{1-3}alkylR^{29}$ (wherein X^{22} represents -O-, -S-, -SO₂-, -NR¹²⁴C(O)-, -NR¹²⁵SO₂- or -NR¹²⁶- (wherein R¹²⁴, R¹²⁵ and R¹²⁶ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim+27);
- 7) R²⁹ (wherein R²⁹ is as defined in claim+27);
- 8) $X^{22}C_{1-4}alkylR^{28}$ (wherein X^{22} and R²⁸ are as defined in claim+27); and
- 9) $R^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$ (wherein q, r, X⁹, R⁵⁴ and R⁵⁵ are as defined in claim+27);
- Q¹ is C₁₋₅alkylQ²⁷ wherein Q²⁷ is selected from:
- 10) W¹Q² (wherein W¹ and Q² are as defined in claim+27);
- 11) Q² (wherein Q² is as defined in claim+27);
- 12) W²C₁₋₄alkylQ² (wherein W² and Q² are as defined in claim+27); and
- 13) Q¹³(C₁₋₄alkyl)_j(W²)_kQ¹⁴ (wherein W², j, k, Q¹³ and Q¹⁴ are as defined in claim+27);
- 14) Q¹³(C₁₋₄alkanoyl)Q¹⁴ⁿ (wherein Q¹³ and Q¹⁴ⁿ are as defined in claim+27), and Q²¹, W⁴, Q²⁸ and Q²⁹ are as defined in claim+27,
- may be prepared by reacting a compound of the formula IX:



(IX)

(wherein L^1 and s are as defined herein, X^1 , R^1 , R^2 , ring C, Z and n are as defined in claim ~~1~~ 27), with one of the compounds of the formulae Xa-e:

$R^{113}-H$	(Xa)
$Q^{27}-H$	(Xb)
$Q^{21}-W^4-H$	(Xc)
$Q^{28}-H$	(Xd)
$Q^{29}-H$	(Xe)

(wherein R^{113} and Q^{27} are as defined herein and Q^{21} , W^4 , Q^{28} and Q^{29} are as defined in claim ~~1~~ 27);

- (e) a compound of the formula I or a salt thereof wherein one or more of the substituents $(R^2)_m$ is represented by $-NR^{127}R^{128}$, where one (and the other is hydrogen) or both of R^{127} and R^{128} are C_{1-3} alkyl, may be effected by the reaction of compounds of formula I wherein the substituent $(R^2)_m$ is an amino group and an alkylating agent; or
- (f) a compound of the formula I or a salt thereof wherein X^1 is $-SO-$ or $-SO_2-$ may be prepared by oxidation from the corresponding compound in which X^1 is $-S-$ or $-SO-$; and optionally forming when a salt of a compound of formula I is required, by reaction of the compound obtained with an acid or base ~~whereby to obtain the desired salt.~~

Claim 20 (currently amended): A pharmaceutical composition which comprises as active ingredient a compound of formula I or a pharmaceutically acceptable salt thereof according to claim ~~1~~ 27, claim 2 or claim 5 in association with a pharmaceutically acceptable excipient or carrier.

Claim 21 (cancelled).

Claim 22 (currently amended): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal; ~~such as a human being,~~ in need of such treatment which comprises administering to said animal an effective amount of

a compound according to claim ~~1~~27, claim 2 or claim 5, or a pharmaceutically acceptable salt thereof.

Claim 23 (original): The compound
7-benzyloxy-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline or a salt thereof.

Claim 24 (original): The compound
4-(4-fluoro-2-methylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline or a salt thereof.


Claim 25 (original): A process for the preparation of 5-bromo-7-azaindole comprising:
step 1: the reduction of 7-azaindole to give 7-azaindoline; followed by
step 2: the bromination of 7-azaindoline to give 5-bromo-7-azaindoline; followed by
step 3: the oxidation of 5-bromo-7-azaindoline to give 5-bromo-7-azaindole.

Claim 26 (original): A process for the production of 5-methoxy-7-azaindole comprising mixing a solution of the following materials in relative quantities according to the amounts given herein:

5-bromo-7-azaindole (8.6 g, 44 mmol), copper (I) bromide (12.6 g, 88 mmol) and sodium methoxide (100 g, 1.85 mol) in a mixture of "degassed" DMF (260 mls) and methanol (175 mls);

stirring the resulting mixture at ambient temperature in a nitrogen atmosphere; and then heating the mixture at reflux.

Claim 27 (new): A compound of the formula I:



(I)

wherein:

ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N and S;

Z is -O- or -S-;

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2 or 3;

R^2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylsulphanyl,

$-NR^3R^4$, wherein R^3 and R^4 , which may be the same or different, each represents hydrogen or C_{1-3} alkyl,

or R^5X^1 - wherein X^1 represents a direct bond, -O-, $-CH_2-$, $-OC(O)-$, $-C(O)-$, -S-, $-SO-$, $-SO_2-$, $-NR^6C(O)-$, $-C(O)NR^7-$, $-SO_2NR^8-$, $-NR^9SO_2-$ or $-NR^{10}-$, wherein R^6 , R^7 , R^8 , R^9 and R^{10} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^5 is selected from one of the following twenty-two groups:

- 1) hydrogen, oxiranyl C_{1-4} alkyl or C_{1-5} alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
- 2) C_{1-5} alkyl $X^2C(O)R^{11}$ wherein X^2 represents -O- or $-NR^{12}-$ in which R^{12} represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{11} represents C_{1-3} alkyl, $-NR^{13}R^{14}$ or $-OR^{15}$, wherein R^{13} , R^{14} and R^{15} which may be the same or different each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl;

- 3) $C_{1-3}alkylX^3R^{16}$ wherein X^3 represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR¹⁷C(O)-, -C(O)NR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹-, wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N,
- which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and
- which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_gringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl;
- 4) $C_{1-3}alkylX^4C_{1-3}alkylX^5R^{22}$ wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR²³C(O)-, -C(O)NR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷-, wherein R²³, R²⁴, R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl and R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl;
- 5) R²⁸, wherein R²⁸ is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_gringD$ wherein f is 0

or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl;

- 6) C₁₋₃alkylR²⁸, wherein R²⁸ is as defined herein;
- 7) C₂₋₃alkenylR²⁸, wherein R²⁸ is as defined herein;
- 8) C₂₋₃alkynylR²⁸, wherein R²⁸ is as defined herein;
- 9) R²⁹, wherein R²⁹ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)NR³⁰R³¹, -NR³²C(O)R³³ wherein R³⁰, R³¹, R³² and R³³, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl and a group -(O)_f(C₁₋₄alkyl)_gringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl;
- 10) C₁₋₃alkylR²⁹, wherein R²⁹ is as defined herein;
- 11) C₂₋₃alkenylR²⁹, wherein R²⁹ is as defined herein;
- 12) C₂₋₃alkynylR²⁹, wherein R²⁹ is as defined herein;
- 13) C₁₋₃alkylX⁶R²⁹ wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR³⁴C(O)-, -C(O)NR³⁵-, -SO₂NR³⁶-, -NR³⁷SO₂- or -NR³⁸-, wherein R³⁴, R³⁵, R³⁶, R³⁷ and R³⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁹ is as defined herein;
- 14) C₂₋₃alkenylX⁷R²⁹ wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR³⁹C(O)-, -C(O)NR⁴⁰-, -SO₂NR⁴¹-, -NR⁴²SO₂- or -NR⁴³-, wherein R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁹ is as defined herein;

- 15) $C_{2-5}alkynylX^8R^{29}$ wherein X^8 represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁴C(O)-, -C(O)NR⁴⁵-, -SO₂NR⁴⁶-, -NR⁴⁷SO₂- or -NR⁴⁸-, wherein R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁹ is as defined herein;
- 16) $C_{1-4}alkylX^9C_{1-4}alkylR^{29}$ wherein X^9 represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁹C(O)-, -C(O)NR⁵⁰-, -SO₂NR⁵¹-, -NR⁵²SO₂- or -NR⁵³-, wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵² and R⁵³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²⁹ is as defined herein;
- 17) $C_{1-4}alkylX^9C_{1-4}alkylR^{28}$, wherein X^9 and R²⁸ are as defined herein;
- 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 20) $C_{2-5}alkenylX^9C_{1-4}alkylR^{28}$, wherein X^9 and R²⁸ are as defined herein;
- 21) $C_{2-5}alkynylX^9C_{1-4}alkylR^{28}$, wherein X^9 and R²⁸ are as defined herein; and
- 22) $C_{1-4}alkylR^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$ wherein X^9 is as defined herein, q is 0 or 1, r is 0 or 1, and R⁵⁴ and R⁵⁵ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)-(C₁₋₄alkyl)_fringD wherein f is 0

or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl, with the proviso that R⁵⁴ cannot be hydrogen;

and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in R⁵X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino;

R¹ represents hydrogen, oxo, halogeno, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₁₋₄alkoxymethyl, C₁₋₄alkanoyl, C₁₋₄haloalkyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₃alkanoyloxy, nitro, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, N-(C₁₋₄alkylsulphonyl)amino, N-(C₁₋₄alkylsulphonyl)-N-(C₁₋₄alkyl)amino, N,N-di(C₁₋₄alkylsulphonyl)amino, a C₃₋₇alkylene chain joined to two ring C carbon atoms, C₁₋₄alkanoylaminoC₁₋₄alkyl, carboxy

or a group R⁵⁶X¹⁰ wherein X¹⁰ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁵⁷C(O)-, -C(O)NR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹-, wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl or

C₁₋₃alkoxyC₂₋₃alkyl, and R⁵⁶ is selected from one of the following twenty-two groups:

- 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
- 2) C₁₋₃alkylX¹¹C(O)R⁶² wherein X¹¹ represents -O- or -NR⁶³-, in which R⁶³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁶² represents C₁₋₃alkyl, -NR⁶⁴R⁶⁵ or -OR⁶⁶, wherein R⁶⁴, R⁶⁵ and R⁶⁶ which may be the same or different each represents hydrogen, C₁₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl;
- 3) C₁₋₅alkylX¹²R⁶⁷ wherein X¹² represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR⁶⁸C(O)-, -C(O)NR⁶⁹-, -SO₂NR⁷⁰-, -NR⁷¹SO₂- or -NR⁷²-, wherein R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ and R⁷² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁶⁷ represents hydrogen, C₁₋₃alkyl, cyclopentyl,

- cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)-(C_{1-4}alkyl)_g ringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl;
- 4) C₁₋₅alkylX¹³C₁₋₅alkylX¹⁴R⁷³ wherein X¹³ and X¹⁴ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR⁷⁴C(O)-, -C(O)NR⁷⁵-, -SO₂NR⁷⁶-, -NR⁷⁷SO₂- or -NR⁷⁸-, wherein R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl and R⁷³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl;
- 5) R⁷⁹, wherein R⁷⁹ is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)-(C_{1-4}alkyl)_g ringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C₁₋₄alkyl;
- 6) C₁₋₅alkylR⁷⁹, wherein R⁷⁹ is as defined herein;
- 7) C₂₋₅alkenylR⁷⁹, wherein R⁷⁹ is as defined herein;

- 8) $C_{2-5}alkynylR^{79}$, wherein R^{79} is as defined herein;
- 9) R^{80} , wherein R^{80} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{1-4}hydroxyalkyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $C_{1-4}hydroxyalkoxy$, carboxy, trifluoromethyl, cyano, $-C(O)NR^{81}R^{82}$, $-NR^{83}C(O)R^{84}$ wherein R^{81} , R^{82} , R^{83} and R^{84} , which may be the same or different, each represents hydrogen, $C_{1-4}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and a group $-(O-)_f(C_{1-4}alkyl)_gringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from $C_{1-4}alkyl$;
- 10) $C_{1-5}alkylR^{80}$, wherein R^{80} is as defined herein;
- 11) $C_{2-5}alkenylR^{80}$, wherein R^{80} is as defined herein;
- 12) $C_{2-5}alkynylR^{80}$, wherein R^{80} is as defined herein;
- 13) $C_{1-5}alkylX^{15}R^{80}$ wherein X^{15} represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{85}C(O)-$, $-C(O)NR^{86}-$, $-SO_2NR^{87}-$, $-NR^{88}SO_2-$ or $-NR^{89}-$, wherein R^{85} , R^{86} , R^{87} , R^{88} and R^{89} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and R^{80} is as defined herein;
- 14) $C_{2-5}alkenylX^{16}R^{80}$ wherein X^{16} represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{90}C(O)-$, $-C(O)NR^{91}-$, $-SO_2NR^{92}-$, $-NR^{93}SO_2-$ or $-NR^{94}-$, wherein R^{90} , R^{91} , R^{92} , R^{93} and R^{94} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and R^{80} is as defined herein;
- 15) $C_{2-5}alkynylX^{17}R^{80}$ wherein X^{17} represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{95}C(O)-$, $-C(O)NR^{96}-$, $-SO_2NR^{97}-$, $-NR^{98}SO_2-$ or $-NR^{99}-$, wherein R^{95} , R^{96} , R^{97} , R^{98} and R^{99} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and R^{80} is as defined herein;
- 16) $C_{1-4}alkylX^{18}C_{1-4}alkylR^{80}$ wherein X^{18} represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{100}C(O)-$, $-C(O)NR^{101}-$, $-SO_2NR^{102}-$, $-NR^{103}SO_2-$ or $-NR^{104}-$, wherein R^{100} ,

R^{101} , R^{102} , R^{103} and R^{104} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl and R^{80} is as defined herein;

17) C_{1-4} alkyl $X^{18}C_{1-4}$ alkyl R^{79} , wherein X^{18} and R^{79} are as defined herein;

18) C_{2-5} alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4} alkylamino, N,N -di(C_{1-4} alkyl)amino, aminosulphonyl, N - C_{1-4} alkylaminosulphonyl and N,N -di(C_{1-4} alkyl)aminosulphonyl;

19) C_{2-5} alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4} alkylamino, N,N -di(C_{1-4} alkyl)amino, aminosulphonyl, N - C_{1-4} alkylaminosulphonyl and N,N -di(C_{1-4} alkyl)aminosulphonyl;

20) C_{2-5} alkenyl $X^{18}C_{1-4}$ alkyl R^{79} , wherein X^{18} and R^{79} are as defined herein;

21) C_{2-5} alkynyl $X^{18}C_{1-4}$ alkyl R^{79} , wherein X^{18} and R^{79} are as defined herein; and

22) C_{1-4} alkyl $R^{105}(C_{1-4}$ alkyl) $_x(X^{18})_yR^{106}$ wherein X^{18} is as defined herein, x is 0 or 1, y is 0 or 1, and R^{105} and R^{106} are each independently selected from hydrogen, C_{1-3} alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3} alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4} alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4} cyanoalkyl, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-4} alkylsulphonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} alkylamino C_{1-4} alkyl, di(C_{1-4} alkyl)amino C_{1-4} alkyl, C_{1-4} alkylamino C_{1-4} alkoxy, di(C_{1-4} alkyl)amino C_{1-4} alkoxy and a group $-(O-)_f(C_{1-4}$ alkyl) $_g$ ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4} alkyl, with the proviso that R^{105} cannot be hydrogen;

and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in R⁵⁶X¹⁰- which is linked to X¹⁰ may bear one or more substituents selected from hydroxy, halogeno and amino;

with the proviso that one or more R¹ and/or one or more R² are selected from one of the following five groups:

(i) Q¹X¹- wherein X¹ is as defined herein and Q¹ is selected from one of the following ten groups:

1) Q², wherein Q² is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl and C₁₋₆fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O)_f(C_{1-4}alkyl)_gringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl;


- 2) $C_{1-5}alkylW^1Q^2$ wherein W^1 represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NQ³C(O)-, -C(O)NQ⁴-, -SO₂NQ⁵-, -NQ⁶SO₂- or -NQ⁷-, wherein Q³, Q⁴, Q⁵, Q⁶ and Q⁷ each independently represents hydrogen, C₁₋₃alkyl, C₁₋₃alkoxyC₂₋₃alkyl, C₂₋₅alkenyl, C₂₋₅alkynyl or C₁₋₄haloalkyl and Q² is as defined herein;
- 3) $C_{1-5}alkylQ^2$, wherein Q² is as defined herein;
- 4) $C_{2-5}alkenylQ^2$, wherein Q² is as defined herein;
- 5) $C_{2-5}alkynylQ^2$, wherein Q² is as defined herein;
- 6) $C_{1-4}alkylW^2C_{1-4}alkylQ^2$ wherein W^2 represents -O-, -S-, -SO-, -SO₂-, -NQ⁸C(O)-, -C(O)NQ⁹-, -SO₂NQ¹⁰-, -NQ¹¹SO₂- or -NQ¹²-, wherein Q⁸, Q⁹, Q¹⁰, Q¹¹ and Q¹² each independently represents hydrogen, C₁₋₃alkyl, C₁₋₃alkoxyC₂₋₃alkyl, C₂₋₅alkenyl, C₂₋₅alkynyl or C₁₋₄haloalkyl and Q² is as defined herein;
- 7) $C_{2-5}alkenylW^2C_{1-4}alkylQ^2$, wherein W^2 and Q² are as defined herein;
- 8) $C_{2-5}alkynylW^2C_{1-4}alkylQ^2$, wherein W^2 and Q² are as defined herein;
- 9) $C_{1-4}alkylQ^{13}(C_{1-4}alkyl)_j(W^2)_kQ^{14}$ wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q¹³ and Q¹⁴ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₆fluoroalkyl, C₁₋₆alkanoyl, aminoC₁₋₆alkanoyl, C₁₋₄alkylaminoC₁₋₆alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₆alkanoyl, C₁₋₆fluoroalkanoyl, carbamoyl, C₁₋₄alkylcarbamoyl, di(C₁₋₄alkyl)carbamoyl, carbamoylC₁₋₆alkyl, C₁₋₄alkylcarbamoylC₁₋₆alkyl, di(C₁₋₄alkyl)carbamoylC₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O)-(C₁₋₄alkyl)_gringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated

heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4} alkyl, with the provisos that Q^{13} cannot be hydrogen and one or both of Q^{13} and Q^{14} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-6} alkanoyl, amino C_{1-6} alkanoyl, C_{1-4} alkylamino C_{1-6} alkanoyl, di(C_{1-4} alkyl)amino C_{1-6} alkanoyl, C_{1-6} fluoroalkanoyl, carbamoyl, C_{1-4} alkylcarbamoyl, di(C_{1-4} alkyl)carbamoyl, carbamoyl C_{1-6} alkyl, C_{1-4} alkylcarbamoyl C_{1-6} alkyl, di(C_{1-4} alkyl)carbamoyl C_{1-6} alkyl, C_{1-6} alkylsulphonyl and C_{1-6} fluoroalkylsulphonyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein;

- 10) C_{1-4} alkyl $Q^{13}C_{1-4}$ alkanoyl Q^{14n} wherein Q^{13} is as defined herein and is not hydrogen and Q^{14n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further nitrogen atom wherein Q^{14n} is linked to C_{1-6} alkanoyl through a nitrogen atom and wherein Q^{14n} optionally bears 1, 2 or 3 substituents selected from C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-6} fluoroalkyl, C_{1-6} alkanoyl, amino C_{1-6} alkanoyl, C_{1-4} alkylamino C_{1-6} alkanoyl, di(C_{1-4} alkyl)amino C_{1-6} alkanoyl, C_{1-6} fluoroalkanoyl, carbamoyl, C_{1-4} alkylcarbamoyl, di(C_{1-4} alkyl)carbamoyl, carbamoyl C_{1-6} alkyl, C_{1-4} alkylcarbamoyl C_{1-6} alkyl, di(C_{1-4} alkyl)carbamoyl C_{1-6} alkyl, C_{1-6} alkylsulphonyl, C_{1-6} fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4} cyanoalkyl, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-4} alkylsulphonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} alkylamino C_{1-4} alkyl, di(C_{1-4} alkyl)amino C_{1-4} alkyl, C_{1-4} alkylamino C_{1-4} alkoxy, di(C_{1-4} alkyl)amino C_{1-4} alkoxy and a group $-(O-)_f(C_{1-4}alkyl)_g$ ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4} alkyl;

and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in Q¹X¹- which is linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino;

- (ii) Q¹⁵W³- wherein W³ represents -NQ¹⁶C(O)-, -C(O)NQ¹⁷-, -SO₂NQ¹⁸-, -NQ¹⁹SO₂- or -NQ²⁰-, wherein Q¹⁶, Q¹⁷, Q¹⁸, Q¹⁹ and Q²⁰ each independently represents C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₄haloalkyl, and Q¹⁵ is C₂₋₅alkenyl or C₂₋₅alkynyl;
- (iii) Q²¹W⁴C₁₋₅alkylX¹- wherein W⁴ represents -NQ²²C(O)-, -C(O)NQ²³-, -SO₂NQ²⁴-, -NQ²⁵SO₂- or -NQ²⁶-, wherein Q²², Q²³, Q²⁴, Q²⁵ and Q²⁶ each independently represents hydrogen, C₁₋₃alkyl, C₁₋₃alkoxyC₂₋₃alkyl, C₂₋₅alkenyl, C₂₋₅alkynyl or C₁₋₄haloalkyl, and Q²¹ represents C₂₋₅alkenyl or C₂₋₅alkynyl, and X¹ is as defined herein;
- (iv) Q²⁸C₁₋₅alkylX¹-, Q²⁸C₂₋₅alkenylX¹- or Q²⁸C₂₋₅alkynylX¹- wherein X¹ is as defined herein and Q²⁸ is an imidazolidinyl group which bears two oxo substituents and one C₁₋₆alkyl or C₃₋₁₀cycloalkyl group which C₁₋₆alkyl or C₃₋₁₀cycloalkyl group may bear a hydroxy substituent on the carbon atom which is linked to the imidazolidinyl group, and wherein the C₁₋₅alkyl, C₁₋₅alkenyl or C₁₋₅alkynyl linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino; and
- (v) Q²⁹C₁₋₅alkylX¹-, Q²⁹C₂₋₅alkenylX¹- or Q²⁹C₂₋₅alkynylX¹- wherein X¹ is as defined herein, the C₁₋₅alkyl, C₁₋₅alkenyl or C₁₋₅alkynyl linked to X¹ may bear one or more substituents selected from hydroxy, halogeno and amino and Q²⁹ is a group 1,4-dioxo-8-azaspiro[4.5]dec-8-yl, which may be represented:



or R¹ may be selected from any of the groups defined herein for R¹ and R² is

6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.